WO2015170562A1 - リンポルフィリン化合物及びその製造方法、並びに生体分子損傷剤 - Google Patents
リンポルフィリン化合物及びその製造方法、並びに生体分子損傷剤 Download PDFInfo
- Publication number
- WO2015170562A1 WO2015170562A1 PCT/JP2015/061717 JP2015061717W WO2015170562A1 WO 2015170562 A1 WO2015170562 A1 WO 2015170562A1 JP 2015061717 W JP2015061717 W JP 2015061717W WO 2015170562 A1 WO2015170562 A1 WO 2015170562A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- tmpp
- biomolecule
- saturated
- unsaturated aliphatic
- Prior art date
Links
- -1 Phosphorus porphyrin compound Chemical class 0.000 title claims abstract description 35
- 239000003795 chemical substances by application Substances 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 16
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 12
- 150000001768 cations Chemical class 0.000 claims abstract description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims abstract description 9
- 125000003277 amino group Chemical group 0.000 claims abstract description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- ABCGFHPGHXSVKI-UHFFFAOYSA-O meso-tetrakis(n-methyl-4-pyridyl)porphine(4+) Chemical compound C1=C[N+](C)=CC=C1C(C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(=N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 ABCGFHPGHXSVKI-UHFFFAOYSA-O 0.000 description 70
- 230000006378 damage Effects 0.000 description 25
- 102000008100 Human Serum Albumin Human genes 0.000 description 19
- 108091006905 Human Serum Albumin Proteins 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000006862 quantum yield reaction Methods 0.000 description 15
- 230000027756 respiratory electron transport chain Effects 0.000 description 15
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 239000003504 photosensitizing agent Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- XSPWLTJTTKJBSD-UHFFFAOYSA-N 5,10,15,20-tetrakis(4-methoxyphenyl)-21,23-dihydroporphyrin hydrochloride Chemical compound Cl.COc1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc([nH]2)c(-c2ccc(OC)cc2)c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc1[nH]2 XSPWLTJTTKJBSD-UHFFFAOYSA-N 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 5
- 150000004032 porphyrins Chemical class 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QCZAJOVYBIIPDI-UHFFFAOYSA-O 5,10,15,20-tetrakis(1-methylpyridin-1-ium-2-yl)-21,22-dihydroporphyrin Chemical compound C[N+]1=CC=CC=C1C(C=1C=CC(N=1)=C(C=1[N+](=CC=CC=1)C)C1=CC=C(N1)C(C=1[N+](=CC=CC=1)C)=C1C=CC(N1)=C1C=2[N+](=CC=CC=2)C)=C2N=C1C=C2 QCZAJOVYBIIPDI-UHFFFAOYSA-O 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003300 photodamaging effect Effects 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 229940123973 Oxygen scavenger Drugs 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- KMYUUNBBYWAVME-UHFFFAOYSA-N [ClH]1[ClH]CC=C1 Chemical compound [ClH]1[ClH]CC=C1 KMYUUNBBYWAVME-UHFFFAOYSA-N 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical class C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- PJOJZHHAECOAFH-UHFFFAOYSA-N 5,10,15,20-tetrakis(4-methoxyphenyl)-21,23-dihydroporphyrin Chemical compound COc1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc([nH]2)c(-c2ccc(OC)cc2)c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc1[nH]2 PJOJZHHAECOAFH-UHFFFAOYSA-N 0.000 description 1
- WDFMGHVUOCNRLB-UHFFFAOYSA-N 5,10,15,20-tetraphenyl-21,23-dihydroporphyrin hydrochloride Chemical compound Cl.c1cc2nc1c(-c1ccccc1)c1ccc([nH]1)c(-c1ccccc1)c1ccc(n1)c(-c1ccccc1)c1ccc([nH]1)c2-c1ccccc1 WDFMGHVUOCNRLB-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001941 photobactericidal effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Definitions
- the present invention relates to a phosphorus porphyrin compound, a method for producing the same, and a biomolecule damaging agent.
- Non-Patent Document 1 discloses dimethoxyline (V) tetraphenylporphyrin chloride (MeO 2 P (V) TPP) and tetrakis (1-methyl-4) as photosensitizers assumed to be used in photodynamic therapy.
- Porphyrin compounds such as -pyridinio) porphyrin (H 2 TMPyP) are disclosed.
- a main object of the present invention is to provide a biomolecule damaging agent capable of damaging biomolecules with high efficiency under low oxygen even when long wavelength light is used.
- the present invention relates to a phosphorus porphyrin compound having a cation represented by the following general formula (1).
- R 1 is a saturated or unsaturated aliphatic hydrocarbon having 1 to 4 carbon atoms which may be substituted with at least one substituent selected from a hydroxyl group, an amino group, an ammonium group and a fluoro group
- R 2 represents a saturated or unsaturated aliphatic hydrocarbon group having 1 to 4 carbon atoms.
- a plurality of R 1 and R 2 in the same molecule may be the same or different.
- a method for producing the above-mentioned limporphyrin compound includes a compound having a cation represented by the following general formula (2) and a compound represented by R 1 OH (R 1 is at least one selected from a hydroxyl group, an amino group, an ammonium group, and a fluoro group) A saturated or unsaturated aliphatic hydrocarbon group having 1 to 4 carbon atoms which may be substituted with a certain substituent.)
- R 1 is at least one selected from a hydroxyl group, an amino group, an ammonium group, and a fluoro group
- R 1 is at least one selected from a hydroxyl group, an amino group, an ammonium group, and a fluoro group
- R 1 is at least one selected from a hydroxyl group, an amino group, an ammonium group, and a fluoro group
- R 1 is at least one selected from a hydroxyl group, an amino group, an ammonium group, and a fluoro group
- X represents a bromo group or a chloro group
- R 2 represents a saturated or unsaturated aliphatic hydrocarbon group having 1 to 4 carbon atoms.
- a plurality of R 2 in the same molecule may be the same or different.
- the present invention relates to a biomolecule damaging agent comprising a phosphorus porphyrin compound having a cation represented by the general formula (1) or (2).
- a biomolecule damaging agent comprising a phosphorus porphyrin compound having a cation represented by the general formula (1) or (2).
- this biomolecule damaging agent even when light having a long wavelength is used, it can function as a photosensitizer for damaging the biomolecule by an electron transfer mechanism from the biomolecule. Therefore, compared with a photosensitizer that damages a biomolecule mainly by a reaction based on the generation of singlet oxygen (active oxygen), the biomolecule can be damaged with higher efficiency under low oxygen.
- the biomolecule damaging agent can be used for damaging biomolecules with light of 550 to 670 nm. Therefore, the biomolecule damaging agent of the present invention can be used for damaging biomolecules by a method including irradiating light of 550 to 670 nm.
- the use of such long-wavelength light for biomolecule damage is advantageous in that it suppresses the influence on the human body and reaches the deep part of the tissue in the living body.
- the biomolecule damaging agent of the present invention even when light having a long wavelength is used, the biomolecule can be damaged with high efficiency under low oxygen.
- the biomolecule damaging agent includes a phosphorus porphyrin compound composed of a cation represented by the following general formula (1) and an arbitrary anion.
- R 1 is a saturated or unsaturated aliphatic hydrocarbon having 1 to 4 carbon atoms which may be substituted with at least one substituent selected from a hydroxyl group, an amino group, an ammonium group and a fluoro group Indicates a group.
- a plurality of R 1 and R 2 in the same molecule may be the same or different.
- the solubility in water can be enhanced while maintaining high sensitivity as a photosensitizer. In order to damage biomolecules in vivo, it is desirable that the photosensitizer has high water solubility.
- R 1 may be an alkyl group having 1 to 4 carbon atoms, or a linear, branched or cyclic alkyl group. These may be substituted by the above substituents.
- R 1 is, for example, a methyl group, an ethyl group, a 2-hydroxyethyl group (—CH 2 CH 2 OH), an n-propyl group, an isopropyl group, a 3-hydroxypropyl group (—CH 2 CH 2 CH 2 OH), It may be an n-butyl group, an isobutyl group, a t-butyl group, or a group formed by substituting one or more hydrogen atoms of these groups with fluorine atoms.
- R 1 having a fluorine atom examples include isomers such as a difluoroethyl group (—CH 2 CHF 2 ), a trifluoroethyl group (—CH 2 CF 3 ), and a trifluoropropyl group (—CH 2 CH 2 CF 3 ).
- Hexafluoropropyl group including isomers such as —CH 2 (CF 3 ) 2
- trifluorobutyl group including isomers such as —CH 2 CH 2 CH 2 CF 3
- hexafluorobutyl Groups including isomers such as —CH 2 CF 2 CHFCF 3
- heptafluorobutyl groups including isomers such as —CH 2 CF 2 CF 2 CF 3
- nonafluorobutyl groups —C (CF 3 And isomers such as 3 ).
- R 1 represents a methyl group, a hydroxyalkyl group having 1 to 4 carbon atoms (such as a 2-hydroxyethyl group or a 3-hydroxypropyl group), an aminomethyl group, or 2-aminoethyl. It can be selected from the group, 3-amino-1-propyl group and 4-amino-1-butyl group.
- R 2 in the formula (1) is a saturated or unsaturated aliphatic hydrocarbon group having 1 to 4 carbon atoms.
- the phosphorus-porphyrin compound in which the porphyrin ring is substituted with such a specific substituted phenyl group can shift the absorption maximum wavelength to a longer wavelength, so that the electron transfer reaction even under low oxygen due to the action of long-wavelength light Can efficiently damage biomolecules.
- R 2 may be a group selected from a methyl group, an ethyl group, and a trifluoroethyl group.
- the biomolecule damaging agent according to another embodiment includes a phosphorus porphyrin compound composed of a cation represented by the following general formula (2) and an arbitrary anion.
- R 2 in the formula (2), and R 2 in the formula (1) is as defined, including preferred embodiments thereof.
- X represents a bromo group or a chloro group. Since the porphyrin ring of the phosphoporphyrin compound having a cation of the formula (2) is substituted with a specific substituted phenyl group, biomolecules are efficiently converted by electron transfer reaction even under low oxygen due to the action of long-wavelength light. Can be damaged.
- the anion constituting the lymphoporphyrin compound is not limited as long as it can function as a counter anion of the cation of formula (1) or (2), but when a biomolecule damaging agent is administered to a living body, it is pharmaceutically
- An anion that forms an acceptable salt is selected.
- Specific examples of anions include halide ions such as Cl ⁇ and Br ⁇ .
- the biomolecule damaging agent may contain only the above-mentioned limporphyrin compound as an active ingredient.
- the biomolecule damaging agent may contain a solvent such as water, or may further contain other optional components.
- the concentration of the phosphorus porphyrin compound in the biomolecule damaging agent may be, for example, 0.01% by mass or more, 90% by mass or more, or 100% by mass or less based on the mass of the biomolecule damaging agent. .
- the biomolecule damaging agent can be used as a photosensitizer for damaging a target cell biomolecule by light irradiation.
- a photosensitizer for photodynamic therapy that includes both administering a biomolecule damaging agent to a patient and selectively damaging a biomolecule of a target cell in the living body by irradiation with light.
- a biomolecule damaging agent can be used.
- the biomolecule damaging agent can also be used as a photobactericidal agent for photobacterial treatment of teeth or gums infected with bacteria.
- the biomolecule damaging agent according to the present embodiment can efficiently attack a biomolecule such as a protein molecule of a target cell by an electron transfer mechanism and kill the target cell even under low oxygen.
- the electron transfer mechanism is a mechanism in which a molecule excited by light irradiation causes oxidative damage to a biomolecule by directly extracting electrons from the biomolecule.
- the electron transfer mechanism can more effectively act on biomolecules even under hypoxia than the singlet oxygen mechanism that requires oxygen.
- Tumor tissues including tumor cells (cancer cells) are generally under hypoxia, but the electron transfer mechanism can efficiently attack target cells under hypoxia such as tumor cells.
- the biomolecule damaging agent according to this embodiment has little influence on the human body and efficiently damages biomolecules by irradiation with light having a long wavelength of about 550 to 670 nm that reaches the deep part of the in vivo tissue. be able to.
- the biomolecule damaging agent can be used as a photosensitizer for damaging biomolecules by a method including irradiating light having a wavelength of 550 to 670 nm.
- the wavelength of light used may be 600 to 670 nm.
- the phosphorus porphyrin compound represented by the formula (2) can be obtained, for example, by a reaction of a substituted tetraphenylporphyrin represented by the following general formula (10) with phosphoryl chloride or phosphoryl bromide.
- a substituted tetraphenylporphyrin of the formula (10) can be easily produced by a person skilled in the art by a known synthetic route starting from substituted benzaldehyde and pyrrole, porphyrin or the like.
- the phosphorus porphyrin compound represented by the formula (1) includes, for example, a phosphorus porphyrin compound having a cation represented by the formula (2) and a compound represented by R 1 OH (R 1 is a hydroxyl group, an amino group, an ammonium group, and A saturated or unsaturated aliphatic hydrocarbon group having 1 to 4 carbon atoms which may be substituted with at least one substituent selected from fluoro groups) to form a phosphorus porphyrin compound.
- R 1 is a hydroxyl group, an amino group, an ammonium group, and A saturated or unsaturated aliphatic hydrocarbon group having 1 to 4 carbon atoms which may be substituted with at least one substituent selected from fluoro groups
- R 1 OH is a hydroxyl group, an amino group, an ammonium group, and A saturated or unsaturated aliphatic hydrocarbon group having 1 to 4 carbon atoms which may be substituted with at least one substituent selected from fluoro groups
- It can manufacture by
- the above process can be performed while heating if necessary.
- the heating temperature varies depending on the starting material, the base, the compound represented by R 1 OH, and other reagents used in the reaction, but the reaction can be performed while heating to reflux.
- the reaction time is usually about several hours to several days. Moreover, this process can be performed on dry conditions.
- the fluorescence lifetime ⁇ f was measured for Cl 2 P (V) TMPP, MeO 2 P (V) TMPP and EG 2 P (V) TMPP. The measurement was performed in a 10 mM phosphate buffer (pH 7.6) using a fluorescence lifetime measuring apparatus (TemPro, manufactured by Horiba, Ltd.).
- Solubility C absorption maximum wavelength ⁇ A max , maximum fluorescence wavelength ⁇ f max , fluorescence quantum yield ⁇ f , Cl 2 P (V) TMPP, MeO 2 P (V) TMPP and EG 2 P (V) TMPP in water
- Table 1 shows the fluorescence lifetime ⁇ f and the singlet oxygen production quantum yield ⁇ ⁇ . The measured absorption spectrum is shown in FIG.
- Cl 2 P (V) TMPP, MeO 2 P (V) TMPP, and EG 2 P (V) TMPP have an absorption maximum wavelength in the vicinity of 550 to 670 nm. confirmed. Moreover, it was confirmed that the absorption wavelengths of MeO 2 P (V) TMPP and EG 2 P (V) TMPP are shifted further to the longer wavelength side than Cl 2 P (V) TMPP. Furthermore, as shown in Table 1, it was confirmed that any compound had a high fluorescence quantum yield and a sufficiently long fluorescence lifetime. Moreover, it was confirmed from the value of a singlet oxygen production
- red light-emitting diode light source ISL-150X150-RR, manufactured by CCS Corporation Irradiation with red light using a wavelength of 659 nm, 2 mW ⁇ cm ⁇ 2
- the autofluorescence of tryptophan residues in HSA at that time was measured using a spectrofluorometer (manufactured by Hitachi High-Tech Fielding Co., Ltd., 650-60) Measured. This autofluorescence intensity is proportional to the amount of undamaged HSA contained in the evaluation solution.
- FIG. 2 is a graph showing the relationship between the irradiation time of red light on the evaluation solution 1 and the amount of damage of HSA.
- the amount of damage (damage rate, slope of the graph of FIG. 2) per unit time of HSA was calculated from the relationship between the irradiation time of red light and the autofluorescence intensity. All the HSA damage in the evaluation liquid 2 was considered to be due to the electron transfer mechanism, and the ratio of the HSA damage speed in the evaluation liquid 2 to the HSA damage speed in the evaluation liquid 1 was calculated as an electron transfer contribution rate.
- ⁇ D (damage rate of HSA) / (number of photons absorbed by the phosphorus porphyrin compound per unit time)
- the damage rate of HSA was calculated from the slope of the approximate line in the graph of FIG.
- the number of photons absorbed per unit time by Cl 2 P (V) TMPP, MeO 2 P (V) TMPP, and EG 2 P (V) TMPP is based on the overlap between the absorption spectrum of each compound and the emission spectrum of the red light-emitting diode light source. Calculated.
- Table 2 shows the evaluation results. Table 2 also shows the protein damage quantum yield ⁇ D of the photosensitizers (MeO 2 P (V) TMPP and H 2 TMPyP) described in Non-Patent Document 1.
- Cl 2 P (V) TMPP, MeO 2 P (V) TMPP, and EG 2 P (V) TMPP have high protein damage quantum yields.
- the quantum yield of protein damage of Cl 2 P (V) TMPP, MeO 2 P (V) TMPP and EG 2 P (V) TMPP is the quantum yield of protein damage of MeO 2 P (V) TMPP and H 2 TMPyP. Much higher than (literature value).
- the fluorescence lifetime ⁇ f * (short lifetime component ⁇ f1 * , long lifetime component ⁇ f2 * ) and electron transfer rate constant k et of TMPP and EG 2 P (V) TMPP are shown in Table 3.
- a single fluorescence lifetime component was confirmed.
- HSA human serum albumin
- a component having a lifetime longer than the fluorescence lifetime ⁇ f and a component having a lifetime shorter than the fluorescence lifetime ⁇ f were observed.
- the component having a long lifetime is considered to be a component having a long lifetime due to suppression of vibration relaxation in the excited state due to the interaction between the phosphorus porphyrin compound and the protein molecule.
- the component having a short lifetime is considered to be a component in which the fluorescence lifetime of the excited singlet state of porphyrin is shortened by extracting electrons from the tryptophan residue of the protein. That is, these results support that the phosphorus porphyrin compound causes protein damage by the electron transfer mechanism.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
1H-NMR(CDCl3,TMS):δ4.03(s,12H,meso-phenyl-OCH3),7.30(d,8H,JH-H=7.5Hz,meso-m-phenyl-H),7.90(d,8H,JH-H=7.5Hz,meso-o-phenyl-H),9.12(d,8H,JH-H=3.0Hz,βH).
FAB-MS:m/z833.2(M+).
1H-NMR(CDCl3,TMS):δ-1.86(d,6H,JP-H=27Hz,P-OCH3),4.04(s,12H,meso-phenyl-OCH3),7.30(d,8H,JH-H=9.0Hz,meso-m-phenyl-H),7.86(d,8H,JH-H=9.0Hz,meso-o-phenyl-H),9.06(d,8H,JH-H=3.0Hz,βH).
FAB-MS:m/z825.3(M+).
1H-NMR(CDCl3,TMS):δ-2.30~-2.22(m,4H,P-OCH2CO),0.71(brs,4H,P-OCCH2O),1.25(s,2H,P-OCCOH),3.99(s,12H,meso-phenyl-OCH3),7.25(d,8H,JH-H=9.0Hz,meso-m-phenyl-H),7.91(d,8H,JH-H=9.0Hz,meso-o-phenyl-H),9.00(brs,8H,βH).
FAB-MS:m/z885.3(M+).
(吸収スペクトル)
Cl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPの吸収スペクトルを、分光光度計(島津製作所,UV-1650PC)を用いて測定した。測定には、10mMリン酸緩衝液(pH7.6)を使用した。
Cl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPについて、蛍光極大波長、蛍光量子収率を測定した。測定は、分光蛍光光度計(株式会社日立ハイテクフィールディング製,F-4500)を用い、10mMリン酸緩衝液(pH7.6)中で行った。
Cl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPについて、蛍光寿命τfを測定した。測定は、蛍光寿命測定装置(株式会社堀場製作所製、TemPro)を用い、10mMリン酸緩衝液(pH7.6)中で行った。
Cl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPの一重項酸素生成量子収率を、以下の方法により算出した。すなわち、近赤外発光分光測定装置(浜松ホトニクス株式会社製,NIR-PIIシステム)により、蒸留水中における一重項酸素の発光強度を測定した。測定された発光強度の、メチレンブルーによる一重項酸素の発光強度(蒸留水中での一重項酸素生成量子収率0.52)に対する相対的な比率を一重項酸素生成量子収率とした。なお、発光強度の測定には、10mMリン酸緩衝液(pH7.6)を使用した。
Cl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPの25℃の蒸留水に対する溶解度を測定した。
Cl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPの光損傷作用を以下の方法により評価した。
5μMのCl2P(V)TMPPと10μMのヒト血清アルブミン(水溶性タンパク質、HSA)をそれぞれ含む1.2mLの10mMリン酸緩衝液(pH7.6)を、Cl2P(V)TMPPの評価用溶液1として調製した。同様にして、MeO2P(V)TMPP及びEG2P(V)TMPPそれぞれについて、評価用溶液1を調製した。
下記式により、タンパク質損傷の量子収率ΦDを算出した。
ΦD=(HSAの損傷速度)/(リンポルフィリン化合物が単位時間当たりに吸収する光子数)
HSAの損傷速度は、図2のグラフの近似直線の傾きから計算した。Cl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPが単位時間当たりに吸収する光子数は、各化合物の吸収スペクトルと赤色発光ダイオード光源の発光スペクトルの重なりから計算した。
評価用液1を用いて、ヒト血清アルブミン(10μM)含有時のCl2P(V)TMPP、MeO2P(V)TMPP及びEG2P(V)TMPPの蛍光寿命τf *(短寿命成分τf1 *、長寿命成分τf2 *)を測定した。その結果と、それぞれの化合物単独の蛍光寿命τfに基づいて、下記式を用いて電子移動速度定数ketを算出した。
Claims (4)
- 550~670nmの光を照射することを含む方法によって生体分子を損傷させるために用いられる、請求項3に記載の生体分子損傷剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016517852A JP6469096B2 (ja) | 2014-05-08 | 2015-04-16 | リンポルフィリン化合物及びその製造方法、並びに生体分子損傷剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-097016 | 2014-05-08 | ||
JP2014097016 | 2014-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015170562A1 true WO2015170562A1 (ja) | 2015-11-12 |
Family
ID=54392415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/061717 WO2015170562A1 (ja) | 2014-05-08 | 2015-04-16 | リンポルフィリン化合物及びその製造方法、並びに生体分子損傷剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6469096B2 (ja) |
WO (1) | WO2015170562A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04120085A (ja) * | 1990-09-10 | 1992-04-21 | Takeo Shimizu | ポルフイリン誘導体 |
WO2011043369A1 (ja) * | 2009-10-07 | 2011-04-14 | 国立大学法人宮崎大学 | 水溶性ポルフィリン及びその製造方法 |
-
2015
- 2015-04-16 JP JP2016517852A patent/JP6469096B2/ja active Active
- 2015-04-16 WO PCT/JP2015/061717 patent/WO2015170562A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04120085A (ja) * | 1990-09-10 | 1992-04-21 | Takeo Shimizu | ポルフイリン誘導体 |
WO2011043369A1 (ja) * | 2009-10-07 | 2011-04-14 | 国立大学法人宮崎大学 | 水溶性ポルフィリン及びその製造方法 |
Non-Patent Citations (3)
Title |
---|
ANDOU, YOSHITO ET AL.: "O-Alkylation of dihydroxo(tetraarylporphyrinato)phosphorus(V) and antimony(V) complexes with alkyl halides", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 75, no. 8, 2002, pages 1757 - 1760, XP055235614 * |
HIRAKAWA, KAZUTAKA ET AL.: "Photosensitized protein damage by dimethoxyphosphorus(V) tetraphenylporphyrin", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 9, May 2013 (2013-05-01), pages 2704 - 2707, XP028546940 * |
SHIMIDZU, TAKEO ET AL.: "Porphyrin arrays connected with molecular wire", THIN SOLID FILMS, vol. 273, no. 1-2, February 1996 (1996-02-01), pages 14 - 19, XP004017463 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2015170562A1 (ja) | 2017-04-20 |
JP6469096B2 (ja) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021503450A (ja) | プログラム可能なポリマー薬 | |
Li et al. | Real-time in situ monitoring via europium emission of the photo-release of antitumor cisplatin from a Eu–Pt complex | |
CN110642852B (zh) | 一种具有线粒体靶向的有机aie光敏探针及其制备方法和应用 | |
Uchoa et al. | Relationship between structure and photoactivity of porphyrins derived from protoporphyrin IX | |
EP2681228A1 (en) | Platinum complexes and their use | |
Hirayama et al. | Bismuth-rhodamine: a new red light-excitable photosensitizer | |
WO2017109217A1 (fr) | Ligands macrocycliques avec groupement(s) picolinate(s), leurs complexes ainsi que leurs utilisations médicales | |
JPWO2008099914A1 (ja) | 蛍光プローブ | |
WO2014055505A1 (en) | Bodipy dyes for biological imaging | |
Gyenge et al. | Photodynamic mechanisms induced by a combination of hypericin and a chlorin based‐photosensitizer in head and neck squamous cell carcinoma cells | |
JP5669123B2 (ja) | 発光によるビタミンc検出法及び定量法 | |
Kuzmina et al. | Development of novel porphyrin/combretastatin A-4 conjugates for bimodal chemo and photodynamic therapy: Synthesis, photophysical and TDDFT computational studies | |
US8545807B2 (en) | Near infrared high emission rare-earth complex | |
JP6469096B2 (ja) | リンポルフィリン化合物及びその製造方法、並びに生体分子損傷剤 | |
RU2621710C1 (ru) | Порфиразин, порфиразиновый комплекс гадолиния и их применение | |
JP6485799B2 (ja) | 三光子励起により発光する発光性組成物 | |
WO2016143699A1 (ja) | ジピリンホウ素錯体及びこれを含有する医薬 | |
Bortolus et al. | Interaction of 4‐Hydroxybiphenyl with Cyclodextrins: Effect of Complex Structure on Spectroscopic and Photophysical Properties | |
Zhou et al. | Novel fluorescent risedronates: Synthesis, photodynamic inactivation and imaging of Bacillus subtilis | |
JP2022036684A (ja) | リンポルフィリン化合物及びその製造方法、並びに生体分子損傷剤 | |
RU2478682C1 (ru) | Люминесцентные координационные соединения лантаноидов для светоизлучающих диодов | |
JP7274134B2 (ja) | 希土類化合物、発光体、発光デバイス、波長変換材料及びセキュリティ材料 | |
JP6089324B2 (ja) | 9−アミノアントラセン又はその誘導体の分解抑制剤及び分解抑制方法、プロトン性有機化合物の検出剤及びプロトン性有機化合物の検出方法 | |
Taniguchi et al. | Photophysical properties and application in live cell imaging of B, B-fluoro-perfluoroalkyl BODIPYs | |
WO2006093251A1 (ja) | 新規光増感剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15789117 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016517852 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC , EPO FORM 1205A DATED 02.02.2017. |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15789117 Country of ref document: EP Kind code of ref document: A1 |